These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23416534)

  • 1. Preclinical pharmacokinetic and toxicological evaluation of MIF-1 peptidomimetic, PAOPA: examining the pharmacology of a selective dopamine D2 receptor allosteric modulator for the treatment of schizophrenia.
    Tan ML; Basu D; Kwiecien JM; Johnson RL; Mishra RK
    Peptides; 2013 Apr; 42():89-96. PubMed ID: 23416534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia.
    Beyaert MG; Daya RP; Dyck BA; Johnson RL; Mishra RK
    Eur Neuropsychopharmacol; 2013 Mar; 23(3):253-62. PubMed ID: 22658400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of PAOPA, a Novel Allosteric Modulator of Dopamine D2 Receptors, on Signaling Proteins Following Sub-Chronic Administration in Rats.
    Daya R; Ho J; Thomson S; Bhandari J; Mishra RK
    Curr Mol Pharmacol; 2021 Oct; 14(4):469-476. PubMed ID: 32912130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the dopamine D2 allosteric modulator, PAOPA, on the expression of GRK2, arrestin-3, ERK1/2, and on receptor internalization.
    Basu D; Tian Y; Bhandari J; Jiang JR; Hui P; Johnson RL; Mishra RK
    PLoS One; 2013; 8(8):e70736. PubMed ID: 23940634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in expression of vesicular protein synapsin II by chronic treatment with D2 allosteric modulator PAOPA.
    Basu D; Tian Y; Hui P; Bhandari J; Johnson RL; Mishra RK
    Peptides; 2015 Apr; 66():58-62. PubMed ID: 25703303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, Pharmacological, and Biological Evaluation of MIF-1 Picolinoyl Peptidomimetics as Positive Allosteric Modulators of D
    Sampaio-Dias IE; Silva-Reis SC; García-Mera X; Brea J; Loza MI; Alves CS; Algarra M; Rodríguez-Borges JE
    ACS Chem Neurosci; 2019 Aug; 10(8):3690-3702. PubMed ID: 31347842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schizophrenia.
    Dyck B; Guest K; Sookram C; Basu D; Johnson R; Mishra RK
    Schizophr Res; 2011 Jan; 125(1):88-92. PubMed ID: 21036015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation of Pro-Leu-Gly-NH2 peptidomimetic positive allosteric modulators of the dopamine D2 receptor into negative modulators.
    Bhagwanth S; Mishra S; Daya R; Mah J; Mishra RK; Johnson RL
    ACS Chem Neurosci; 2012 Apr; 3(4):274-84. PubMed ID: 22860194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG).
    Mishra RK; Marcotte ER; Chugh A; Barlas C; Whan D; Johnson RL
    Peptides; 1997; 18(8):1209-15. PubMed ID: 9396063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of high-affinity CNS dopamine D2 receptor by L-pro-L-leu-glycinamide (PLG) analogue 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide.
    Mishra RK; Srivastava LK; Johnson RL
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):821-7. PubMed ID: 1981396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dopamine Allosteric Agent, PAOPA, Demonstrates Therapeutic Potential in the Phencyclidine NMDA Pre-clinical Rat Model of Schizophrenia.
    Daya RP; Bhandari J; Kooner SK; Ho J; Rowley CD; Bock NA; Farncombe T; Mishra RK
    Front Behav Neurosci; 2018; 12():302. PubMed ID: 30618660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.
    Sharma S; Paladino P; Gabriele J; Saeedi H; Henry P; Chang M; Mishra RK; Johnson RL
    Peptides; 2003 Feb; 24(2):313-9. PubMed ID: 12668218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.
    Luedtke RR; Rangel-Barajas C; Malik M; Reichert DE; Mach RH
    Curr Pharm Des; 2015; 21(26):3700-24. PubMed ID: 26205291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, Pharmacological, and Biological Evaluation of 2-Furoyl-Based MIF-1 Peptidomimetics and the Development of a General-Purpose Model for Allosteric Modulators (ALLOPTML).
    Sampaio-Dias IE; Rodríguez-Borges JE; Yáñez-Pérez V; Arrasate S; Llorente J; Brea JM; Bediaga H; Viña D; Loza MI; Caamaño O; García-Mera X; González-Díaz H
    ACS Chem Neurosci; 2021 Jan; 12(1):203-215. PubMed ID: 33347281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1).
    Marcotte ER; Chugh A; Mishra RK; Johnson RL
    Peptides; 1998; 19(2):403-6. PubMed ID: 9493876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy.
    Pani L; Pira L; Marchese G
    Eur Psychiatry; 2007 Jul; 22(5):267-75. PubMed ID: 17419008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of agonist stimulated adenylyl cyclase and GTPase activity by L-pro-L-leu-glycinamide and its peptidomimetic analogue in rat striatal membranes.
    Mishra RK; Makman MH; Costain WJ; Nair VD; Johnson RL
    Neurosci Lett; 1999 Jul; 269(1):21-4. PubMed ID: 10821635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ-gelling starch nanoparticle (SNP)/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide.
    Majcher MJ; Babar A; Lofts A; Leung A; Li X; Abu-Hijleh F; Smeets NMB; Mishra RK; Hoare T
    J Control Release; 2021 Feb; 330():738-752. PubMed ID: 33383097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.
    Sanyal S; Van Tol HH
    J Psychiatr Res; 1997; 31(2):219-32. PubMed ID: 9278187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
    Wilson JM; Sanyal S; Van Tol HH
    Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.